Viridian Therapeutics Inc... (VRDN)
NASDAQ: VRDN
· Real-Time Price · USD
13.74
0.19 (1.40%)
At close: May 01, 2025, 3:59 PM
13.54
-1.49%
After-hours: May 01, 2025, 05:09 PM EDT
Company Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases.
It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.
The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.
Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Stephen F. Mahoney J.D., MBA |
Contact Details
Address: 221 Crescent Street Waltham, Massachusetts United States | |
| Website | https://www.viridiantherapeutics.com |
Stock Details
| Ticker Symbol | VRDN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590750 |
| CUSIP Number | 92790C104 |
| ISIN Number | US92790C1045 |
| Employer ID | 47-1187261 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Stephen F. Mahoney J.D., MBA | Chief Executive Officer, President & Director |
| Seth Harmon | Chief Financial Officer |
| Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Anthony Casciano | Chief Commercial Officer |
| Christian Zdybowicz | Senior Vice President of Portfolio Strategy & Leadership |
| Diane Stroehmann M.S., R.A.C. | Senior Vice President of Regulatory Affairs |
| Kirk Bertelsen | Senior Vice President & Head of Research |
| Kyle B. Haraldsen | Chief Technical Operations Officer |
| Melissa Manno | Chief Human Resources Officer |
| Shan Wu Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 11, 2025 | SCHEDULE 13G | Filing |
| Apr 09, 2025 | 4 | Filing |
| Apr 09, 2025 | 3 | Filing |
| Apr 07, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 4 | Filing |
| Mar 12, 2025 | 3 | Filing |
| Mar 12, 2025 | 4 | Filing |